Novosound Appoints Medical Tech Veteran Gary Beale as Executive Vice Chairman

Novosound Appoints Medical Tech Veteran Gary Beale as Executive Vice Chairman

Industry leader to spearhead novosound’s medical division as company advances towards FDA clearance for breakthrough ultrasound-based blood pressure monitoring platform

Novosound announces the appointment of renowned medical technology executive Gary Beale as Executive Vice Chairman. In this role, Gary will lead the company’s medical business as novosound moves toward securing FDA clearance for its revolutionary cuffless, continuous and calibration-free blood pressure monitoring device, powered by its proprietary ultrasound platform.

Beale is best known as the founder and CEO of Emblation, a global medical technology company, and brings a wealth of experience from senior leadership roles at Microsulis (now part of AngioDynamics) and Boston Scientific, one of the world’s leading healthcare companies. Over the past two decades, he has built a track record of scaling MedTech businesses and securing significant international partnerships.

Dr. Dave Hughes, CEO and Founder of novosound, commented:

“Gary brings unmatched experience in commercializing medical technology and forging strategic global alliances. His appointment comes at a pivotal time for novosound as we focus on transforming our next-generation ultrasound platform into FDA-cleared medical products. We are thrilled to welcome Gary to the leadership team to drive our medical business forward.“

Gary Beale, Executive Vice Chairman of novosound, said:

“Novosound is one of Scotland’s most innovative companies and is entering a transformative phase. As we advance toward FDA clearance for our ultrasound-based blood pressure monitoring solution, I believe this technology will redefine global standards in health monitoring and unlock substantial commercial opportunities in the digital health space.”

Novosound’s innovative ultrasound sensor enables real-time, calibration-free, continuous blood pressure monitoring by directly measuring arterial distention. Unlike traditional cuff-based devices, novosound’s sensor technology has the capability to integrate seamlessly into wearable devices, opening up pathways for partnerships with leading smartwatch, fitness tracker, and medical device manufacturers.

Dr. Hughes added:

“The health wearables market is at an inflection point. Rather than competing with established players, novosound aims to collaborate through licensing, co-development, and hardware integration. Our mission is to deliver accurate, scalable blood pressure monitoring technology into the hands of consumers and clinicians globally.”

Earlier this year, novosound launched a Special Interest Group (SIG) in collaboration with Technology Scotland and the University of Glasgow, reinforcing its leadership in wearable ultrasound innovation. The SIG aims to establish Scotland as a global hub in the rapidly growing wearable technology sector, projected to reach £150 billion globally.

Novosound’s patented thin-film ultrasound platform and AI-powered instrumentation are unlocking new possibilities in both medical diagnostics and digital health applications. The company has previously announced collaborations with Nasdaq-listed PAVmed and Aspira Medical, a Texas Medical Center spin-out.